Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Dianthus Therapeutics, Inc.

Contributing Author

Recent Articles by Dianthus Therapeutics, Inc.

Aug-04
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results DNTH GlobeNewswire
Aug-04
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases DNTH GlobeNewswire
Aug-03
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) DNTH GlobeNewswire
Jul-02
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) DNTH GlobeNewswire
Jun-29
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis DNTH GlobeNewswire
Jun-02
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH -8.81% GlobeNewswire
May-26
Dianthus Therapeutics to Participate in Two Investor Conferences DNTH GlobeNewswire
May-05
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results DNTH GlobeNewswire
May-01
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire
Apr-06
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire
Mar-12
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares DNTH -6.43% GlobeNewswire
Mar-10
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering DNTH GlobeNewswire
Mar-09
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering DNTH +21.52% GlobeNewswire
Mar-09
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results DNTH +21.52% GlobeNewswire
Mar-09
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH +21.52% GlobeNewswire
Mar-08
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH GlobeNewswire
Mar-03
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH DNTH +11.99% GlobeNewswire
Feb-24
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference DNTH GlobeNewswire
Feb-05
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 DNTH GlobeNewswire
Jan-05
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference DNTH -7.03% GlobeNewswire
Dec-23
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) DNTH GlobeNewswire
Nov-24
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference DNTH +5.38% GlobeNewswire
Nov-05
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results DNTH DNTH +8.00% GlobeNewswire
Nov-04
Dianthus Therapeutics to Participate in Four Investor Conferences During November DNTH GlobeNewswire
Oct-29
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting DNTH GlobeNewswire
Oct-16
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases DNTH GlobeNewswire
Oct-02
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting DNTH -5.14% GlobeNewswire
Sep-11
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares DNTH GlobeNewswire
Sep-09
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering DNTH +6.55% GlobeNewswire
Sep-08
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering DNTH +20.00% GlobeNewswire
Sep-08
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile DNTH +20.00% GlobeNewswire
Sep-07
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis DNTH GlobeNewswire
Aug-07
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results DNTH -6.08% GlobeNewswire
May-29
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference DNTH GlobeNewswire
May-22
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors DNTH GlobeNewswire
May-12
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results DNTH DNTH -6.18% GlobeNewswire
May-05
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September DNTH GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)